---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-075679"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:36.433373+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Longeveron Q2 2025 net loss $10M; HLHS trial fully enrolled, BLA filing targeted late 2026

## Summary
- Revenue for H1 2025 $0.7M (-31% YoY); net loss $10.0M vs $7.5M in H1 2024.
- ELPIS II Phase 2b trial for HLHS fully enrolled (40 patients); top-line results expected Q3 2026.
- BLA submission for HLHS anticipated in late 2026 contingent on positive trial results.
- FDA approved IND for pediatric dilated cardiomyopathy; Phase 2 trial expected H1 2026.
- Cash $10.3M as of June 30; with $5M public offering, runway into Q1 2026; seeks additional financing.

## SEC filing metadata
- accession: 0001213900-25-075679
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390025075679/0001213900-25-075679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390025075679/ea0252837-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-075679
- JSON: https://secwatch.observer/filing/0001213900-25-075679.json
- Plain text: https://secwatch.observer/filing/0001213900-25-075679.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.